Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venous Thrombosis Risk Markers in Women with Polycystic Ovary Syndrome Using Estetrol/Drospirenone vs Ethinyl Estradiol/Drospirenone
TCTR20260128003Phase 0Not yet recruiting
- Sponsor
- Faculty of Medicine, Prince of Songkhla University
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, randomised trial in polycystic ovary syndrome (PCOS) comparing Estetrol + drospirenone with Ethinyl estradiol + drospirenone (2 arms). Primary endpoint: Primary venous thrombosis risk markers. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
estetrolethinyl estradioldrospirenone
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on TCTR20260128003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260128003.